secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001628280-24-005048
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M
---------------------------------------------------------------------------

- Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.
- Full-year 2023 revenue $482.4M (+20% YoY); net income $106.1M ($0.94 diluted EPS).
- Cash and investments $425.4M; 2024 revenue guidance reiterated at $600-$630M.
- NDA for relacorilant in Cushing's expected Q2 2024; GRACE results Q2; CATALYST shows 24% hypercortisolism prevalence in first 700 patients.
- ROSELLA ovarian cancer trial and DAZALS ALS trial results expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/cort-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-005048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer